Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22388885 | 0.82 | TSHR (0.30) | TSHRTDP1 | |
| SCHEMBL9281652 | 0.82 | TSHR (0.37) | TSHRTDP1 | |
| SCHEMBL24655048 | 0.78 | — | — | |
| SCHEMBL23903220 | 0.76 | TSHR (0.30) | TSHRTDP1 | |
| SCHEMBL6004329 | 0.74 | TSHR (0.40) | TSHRTDP1 | |
| SCHEMBL24837140 | 0.74 | — | — | |
| SCHEMBL22269215 | 0.73 | TSHR (0.33) | TSHRTDP1 | |
| SCHEMBL3789192 | 0.73 | CYP2D6 (0.37) | — | |
| SCHEMBL543870 | 0.73 | MEN1 (0.31) | — | |
| SCHEMBL356997 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| CN-109563043-A | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-107406422-A | Pyrazole derivatives as sGC stimulants | 铁木医药有限公司 | 2017-11-28 | — | — | CN | disclosed |
| EP-2427425-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| EP-2265617-B1 | SOLVENTS | BIONIQS LTD (GB) | 2014-07-02 | — | — | EP | disclosed |
| US-8158626-B2 | Thiazolopyrimidine PI3K inhibitor compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-17 | — | — | US | disclosed |
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7893059-B2 | Thiazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| WO-2009034329-A1 | SOLVENTS | BIONIQS LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20060186419-A1 | Light-emitting device | KABUSHIKI KAISHA TOSHIBA (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-0838508-B1 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORP (JP) | 2001-08-29 | — | — | EP | disclosed |
| US-5871572-A | COLORANT, WATER, A WATER-SOLUBLE ORGANIC SOLVENT, AND PECTIC ACID | SEIKO EPSON CORPORATION (JP) | 1999-02-16 | — | — | US | disclosed |
| EP-0838508-A2 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORPORATION (JP) | 1998-04-29 | — | — | EP | disclosed |
| CN-1099384-A | Process for preparing isocyanates | MONSANTO CO (US) | 1995-03-01 | — | — | CN | disclosed |
| CN-85106982-A | bicyclic compound and preparation method thereof | — | 1987-05-20 | — | — | CN | disclosed |
| EP-0183391-A2 | Synthesis of molecular sieving metallosilicates using silica-transition metal oxide sols | THE STANDARD OIL COMPANY (US) | 1986-06-04 | — | — | EP | disclosed |
| US-4358588-A | 7-/D-ALPHA-AMINO/P-HYDROXYPHENYL/ACETAMIDO-3- CEPHEM-4-CARBOXYLIC ACID DERIVATIVES; EFFICIENCY | GIST-BROCADES N.V. (NL) | 1982-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PIK3CB, PIK3C2B | TSHR 4082/4885TDP1 674/4885 |
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | TSHR 2372/4885TDP1 660/4885 |
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | TSHR 4783/4885TDP1 1631/4885 |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | TSHR 866/4885TDP1 1640/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | TSHR 638/4885TDP1 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.